Compare GXO Logistics Inc (GXO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Neurocrine Biosciences Inc — how do they compare? GXO Logistics Inc trades at $46.56 (market cap $5.32B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.7× GXO Logistics Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GXO | NBIX | |
|---|---|---|
Market Cap | $5.32B | $14.36B |
Volume | 1,255,816 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $65.59 | $185.50 |
52-Week Low | $44.17 | $123.10 |
Typical Hold Time | 28 Days | 23 Days |
Enterprise Value | $10.67B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.36, up 0.8% with neutral technical indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and strong analyst support (88.9% buy ratings). Recent strategic partnerships with Columbia Sportswear and aerospace/defense expansion signal growth potential, though margins remain thin with net income at 0.96%.
GXO presents a compelling growth story with 42% upside to consensus price target of $66.67. Key catalysts include logistics industry recovery and operational efficiency initiatives, but investors face margin pressure risks and competitive threats in the contract logistics space that could limit profitability expansion.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
